Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) closed the day trading at $9.08 down -7.54% from the previous closing price of $9.82. In other words, the price has decreased by -$0.74 from its previous closing price. On the day, 1322854 shares were traded. RXRX stock price reached its highest trading level at $9.52 during the session, while it also had its lowest trading level at $8.81.
For a better understanding of RXRX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.80 and its Current Ratio is at 5.80. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, KeyBanc Capital Markets on September 16, 2022, initiated with a Overweight rating and assigned the stock a target price of $20.
On April 18, 2022, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $10.
SVB Leerink Downgraded its Outperform to Mkt Perform on March 04, 2022, while the target price for the stock was maintained at $10.
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 17 when Larson Tina Marriott sold 16,000 shares for $10.96 per share. The transaction valued at 175,402 led to the insider holds 203,654 shares of the business.
Borgeson Blake sold 17,770 shares of RXRX for $197,610 on Nov 16. The Director now owns 7,654,927 shares after completing the transaction at $11.12 per share. On Nov 15, another insider, Virani Shafique, who serves as the Chief Business Officer of the company, sold 10,000 shares for $12.31 each. As a result, the insider received 123,123 and left with 83,160 shares of the company.
For the stock, the TTM Price-to-Sale (P/S) ratio is 66.69 while its Price-to-Book (P/B) ratio in mrq is 4.05.
Stock Price History:
Over the past 52 weeks, RXRX has reached a high of $21.19, while it has fallen to a 52-week low of $4.92. The 50-Day Moving Average of the stock is 11.01, while the 200-Day Moving Average is calculated to be 8.96.
Over the past 3-months, RXRX traded about 1.16M shares per day on average, while over the past 10 days, RXRX traded about 1.44M shares per day. A total of 173.44M shares are outstanding, with a floating share count of 160.95M. Insiders hold about 5.50% of the company’s shares, while institutions hold 68.70% stake in the company. Shares short for RXRX as of Oct 13, 2022 were 15.55M with a Short Ratio of 15.80M, compared to 14.39M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 8.98% and a Short% of Float of 13.23%.
Current recommendations for the stock of the company come from 4 analysts. On average, analysts expect EPS of -$0.38 for the current quarter, with a high estimate of -$0.35 and a low estimate of -$0.43, while EPS last year was -$0.28. The consensus estimate for the next quarter is -$0.29, with high estimates of -$0.11 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$1.17 and -$1.76 for the fiscal current year, implying an average EPS of -$1.46. EPS for the following year is -$1.58, with 5 analysts recommending between -$1.24 and -$2.02.
4 analysts predict $6.97M in revenue for the current quarter. It ranges from a high estimate of $8M to a low estimate of $5.6M. As of the current estimate, Recursion Pharmaceuticals Inc.’s year-ago sales were $2.53M, an estimated increase of 175.10% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $30.15M, an increase of 1,090.30% over than the figure of $175.10% in the same quarter last year. There is a high estimate of $63M for the next quarter, whereas the lowest estimate is $8M.
A total of 5 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $83M, while the lowest revenue estimate was $28.81M, resulting in an average revenue estimate of $48.56M. In the same quarter a year ago, actual revenue was $10.18M, up 377.10% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $63.34M in the next fiscal year. The high estimate is $121M and the low estimate is $35M. The average revenue growth estimate for next year is up 30.40% from the average revenue estimate for this year.